Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 23, 2004. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
The primary material change reported is a reduction in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of July 22, 2004, the fund's holdings decreased from 19,061,552 to 19,033,614 shares. This movement occurred at an average price of $39.39 per share.
Outlook and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. It notes that two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund as beneficiaries, similar to other employees.
Key Facts for Investors
- Share Reduction: The US Retirement Savings Plan reduced its ADR holdings by 27,938 shares.
- Transaction Price: The average price for the movement was $39.39.
- Director Interest: Directors Dr. J.P. Garnier and Dr. T. Yamada have potential interests in the fund's holdings.
- No Financial Data: This filing does not contain operational or financial performance metrics for the company.